Jazz Pharmaceuticals (JAZZ)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 120.4 |
Market Cap | 7.30B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 7.06 |
PE Ratio (ttm) | 17.11 |
Forward PE | n/a |
Analyst | Buy |
Ask | 121.2 |
Volume | 23,088 |
Avg. Volume (20D) | 595,293 |
Open | 121.47 |
Previous Close | 121.18 |
Day's Range | 120.34 - 121.52 |
52-Week Range | 99.06 - 134.17 |
Beta | undefined |
About JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include ...
Analyst Forecast
According to 14 analyst ratings, the average rating for JAZZ stock is "Buy." The 12-month stock price forecast is $174, which is an increase of 44.04% from the latest price.
Next Earnings Release
Analysts project revenue of $1.06B, reflecting a 4.74% YoY growth and earnings per share of 5.79, making a 15.34% increase YoY.